Nefomed (Nefopam Hydrochloride)

Nefopam Hydrochloride produces analgesia by inhibiting the re‑uptake of the neurotransmitters norepinephrine, serotonin and dopamine in the central nervous system, and by blocking voltage‑gated sodium channels. This multimodal action reduces the transmission of pain signals and modulates central pain pathways without acting on opioid receptors.

The specific dose and frequency of Nefomed are determined by the prescribing clinician based on the severity of pain, patient characteristics and clinical setting. The product is supplied as an injectable solution for intramuscular administration, and the prescriber will set the appropriate volume and dosing interval for each individual case.

Safety data for Nefopam Hydrochloride in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Consequently, it should only be used during pregnancy or while breastfeeding if the potential benefit justifies the potential risk to the fetus or infant, and after careful evaluation by a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Nefomed. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details—including any cold‑chain requirements—and assists with import documentation.

Compared with opioid analgesics, Nefomed offers pain relief without the risk of respiratory depression, dependence or typical opioid‑related side effects. Relative to other non‑opioid agents such as NSAIDs, Nefopam does not inhibit cyclo‑oxygenase enzymes, so it carries a lower risk of gastrointestinal bleeding and platelet inhibition. However, its side‑effect profile includes anticholinergic symptoms and rare serious reactions, which should be weighed against alternative therapies.

Nefomed injection should be stored at 2‑8 °C (refrigerated) in its original packaging. It must be protected from light, should not be frozen, and should be gently inverted if mixing is required—avoid shaking the vial. Prior to administration, inspect the solution for particulate matter or discoloration and discard any product that appears compromised.

Nefomed is supplied as a sterile injectable solution intended for intramuscular injection. The healthcare professional selects an appropriate muscle site, typically the deltoid or gluteal muscle, and administers the prescribed volume using a sterile needle and syringe. Proper aseptic technique and correct injection depth are essential to ensure effective analgesia and minimize injection‑site reactions.

Although uncommon, serious adverse reactions to Nefomed can include seizures, severe hypotension, cardiac arrhythmias, anaphylactic or anaphylactoid reactions, agranulocytosis, and severe skin disorders such as Stevens‑Johnson syndrome. Patients should be monitored for any signs of these events, and immediate medical attention is required if they occur. Prompt discontinuation of the drug is recommended upon identification of a serious reaction.

Nefomed is contraindicated in patients with known hypersensitivity to Nefopam or any component of the formulation. It should also be avoided in individuals with a history of seizures, uncontrolled hypertension, severe cardiac disease, or those currently receiving monoamine oxidase inhibitors. Caution is advised in patients with renal or hepatic impairment, and the drug should be used only under medical supervision in these populations.